These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 24577256

  • 1. Severity but not comorbidities predicts response to methylphenidate in adults with attention-deficit/hyperactivity disorder: results from a naturalistic study.
    Victor MM, Rovaris DL, Salgado CA, Silva KL, Karam RG, Vitola ES, Picon FA, Contini V, Guimarães-da-Silva PO, Blaya-Rocha P, Belmonte-de-Abreu PS, Rohde LA, Grevet EH, Bau CH.
    J Clin Psychopharmacol; 2014 Apr; 34(2):212-7. PubMed ID: 24577256
    [Abstract] [Full Text] [Related]

  • 2. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
    Manor I, Rozen S, Zemishlani Z, Weizman A, Zalsman G.
    Clin Neuropharmacol; 2011 Apr; 34(4):148-54. PubMed ID: 21738027
    [Abstract] [Full Text] [Related]

  • 3. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

  • 8. Neurocognitive performance and behavioral symptoms in patients with attention-deficit/hyperactivity disorder during twenty-four months of treatment with methylphenidate.
    Wang LJ, Chen CK, Huang YS.
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):246-53. PubMed ID: 25574708
    [Abstract] [Full Text] [Related]

  • 9. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?
    Golubchik P, Kodesh A, Weizman A.
    Clin Neuropharmacol; 2013 Apr; 36(5):141-5. PubMed ID: 24045603
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [Abstract] [Full Text] [Related]

  • 11. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 12. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
    Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE.
    Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report.
    Golubchik P, Sever J, Weizman A, Zalsman G.
    Clin Neuropharmacol; 2011 May; 34(3):108-10. PubMed ID: 21586916
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder].
    Sobanski E, Alm B, Krumm B.
    Nervenarzt; 2007 Mar; 78(3):328-30, 333-37. PubMed ID: 16544121
    [Abstract] [Full Text] [Related]

  • 17. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study.
    Prada P, Nicastro R, Zimmermann J, Hasler R, Aubry JM, Perroud N.
    Atten Defic Hyperact Disord; 2015 Sep; 7(3):199-209. PubMed ID: 25634471
    [Abstract] [Full Text] [Related]

  • 18. Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.
    Maia CR, Matte BC, Ludwig HT, Rohde LA.
    Eur Child Adolesc Psychiatry; 2008 Apr; 17(3):133-42. PubMed ID: 17846812
    [Abstract] [Full Text] [Related]

  • 19. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, Liu HJ, Huang YS, Cheng H, Hsu YC, Liu SI, Pan CH, Huang YF, Huang CF, Wu YY, Huang YH, Liu HC, Chang HL.
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [Abstract] [Full Text] [Related]

  • 20. Association between attention-deficit/hyperactivity disorder and sleep impairment in adulthood: evidence from a large controlled study.
    Surman CB, Adamson JJ, Petty C, Biederman J, Kenealy DC, Levine M, Mick E, Faraone SV.
    J Clin Psychiatry; 2009 Nov; 70(11):1523-9. PubMed ID: 19646365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.